Pragma Pharmaceuticals to re-launch once daily Moxatag
In March 2014, Pragma acquired Moxatag from Shionogi and has been working to make the product available in time for the upcoming cold and flu season. Pragma spokesperson
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted